Wednesday , March 29 2017
Home / Specialty Pharmacy

Specialty Pharmacy

FDA Approves Newron’s Xadago for Treatment of Patients with Parkinson’s Disease

Milan, Italy and Morristown, NJ, U.S.A., – March 21, 2017 – Newron Pharmaceuticals S.p.A. (“Newron”, SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain, and its partners Zambon S.p.A. and US WorldMeds, LLC, announced today …

Read More »

X-Chem and Astellas Pharma Enter Strategic Collaboration Across Multiple Therapeutic Areas

WALTHAM, Mass.–(BUSINESS WIRE)–X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, announced the signing of a broad drug discovery collaboration with Astellas Pharma Inc. (Astellas). The collaboration will enable the discovery of novel lead compounds for complex …

Read More »

Routine Blood Tests Can Help Measure A Patient’s Future Risk for Chronic Disease, New Study Finds

A new study by researchers at the Intermountain Medical Center Heart Institute in Salt Lake City finds that combining information from routine blood tests and age of primary care patients can create a score that measures future risk of chronic disease. This simple risk score, termed the Intermountain Chronic Disease …

Read More »

Amgen’s PCSK9 Inhibitor Repatha Meets Primary Endpoint in Late-Stage Clinical Trial

THOUSAND OAKS, Calif., March 14, 2017 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that four-year follow-up results from the Repatha® (evolocumab) OSLER-1 study, the longest PCSK9 inhibitor clinical trial to date, were published in JAMA Cardiology. Repatha, when added to standard of care (SOC), achieved median low-density lipoprotein cholesterol (LDL-C) reductions …

Read More »

FDA Grants Priority Review to Teva’s Tardive Dyskinesia Drug

JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for SD-809 (deutetrabenazine) for the treatment of tardive dyskinesia (TD). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal …

Read More »

Merck Halts Alzheimer’s Disease Clinical Trial due to Lack of Efficacy

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it will be stopping protocol 017, also known as the EPOCH study, a Phase 2/3 study evaluating verubecestat, an investigational small molecule inhibitor of the beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), …

Read More »

Acorda Therapeutics’ Inhaled Drug Successfully Reduces Parkinson’s Disease Symptoms in Late-Stage Study

ARDSLEY, N.Y.–(BUSINESS WIRE)– Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced Phase 3 clinical data of CVT-301, showing a statistically significant improvement in motor function in people with Parkinson’s disease experiencing OFF periods. CVT-301 is an investigational, inhalable formulation of levodopa (L-dopa). It is being studied as a treatment for OFF periods …

Read More »

Express Scripts Fights Back Against Irresponsible Drug Pricing

LOUIS, Feb. 6, 2017 /PRNewswire/ — Express Scripts’ (NASDAQ: ESRX) efforts to put medicine within reach for payers and patients effectively held the 2016 growth rate in prescription drug spending to just 3.8 percent – a 27 percent decrease from 2015 – according to the 21st edition of its annual …

Read More »

PMC Analysis: Personalized Medicines Top 20 Percent of FDA Approvals For Third Straight Year

WASHINGTON (January 24, 2017) — A new report from the Personalized Medicine Coalition (PMC) shows that in 2016, for the third year in a row, personalized medicines accounted for more than 20 percent of the new molecular entities (NMEs) approved by the U.S. Food and Drug Administration (FDA). PMC President …

Read More »

AbbVie Starts Mid-Stage Trial Programs for ABBV-8E12 in Early Alzheimer’s Disease and Progressive Supranuclear Palsy

NORTH CHICAGO, Ill., Jan. 25, 2017 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced the start of two Phase 2 clinical trial programs to evaluate ABBV-8E12, an investigational anti-tau antibody, in patients with early Alzheimer’s disease and progressive supranuclear palsy (PSP). In recognition of the lack of treatment …

Read More »